Detalles de la búsqueda
1.
Population pharmacokinetics and exposure-response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2-targeted regimens.
Br J Clin Pharmacol
; 83(12): 2767-2777, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-28733983
2.
Exposure-efficacy relationship of vedolizumab subcutaneous and intravenous formulations in Crohn's disease and ulcerative colitis.
Expert Rev Clin Pharmacol
; 17(4): 403-412, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38441048
3.
A Phase I, Open-Label, Fixed Sequence Study to Investigate the Effect of Cytochrome P450 2D6 Inhibition on the Pharmacokinetics of Ulotaront in Healthy Subjects.
Clin Pharmacokinet
; 62(12): 1755-1763, 2023 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-37882999
4.
Combining patient-level and summary-level data for Alzheimer's disease modeling and simulation: a ß regression meta-analysis.
J Pharmacokinet Pharmacodyn
; 39(5): 479-98, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22821139
5.
Population pharmacokinetic analysis of ulotaront in subjects with schizophrenia.
CPT Pharmacometrics Syst Pharmacol
; 10(10): 1245-1254, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34292664
6.
Exposure-response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor.
CPT Pharmacometrics Syst Pharmacol
; 10(11): 1422-1432, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34585528
7.
Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer.
Cancer Chemother Pharmacol
; 84(1): 175-185, 2019 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31102024
8.
Exposure-response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane.
Cancer Chemother Pharmacol
; 80(6): 1079-1090, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-29022084
9.
A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: an example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus.
BMJ Open
; 3(3)2013 Mar 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-23468467
Resultados
1 -
9
de 9
1
Próxima >
>>